Argos Therapeutics

Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.

Argos Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $43.0B in funding across 180 round(s). With a team of 101-250 employees, Argos Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series D - Argos Therapeutics, raised $25.0M. Discover more about their projects, partnerships, and impact on our platform.